Medical - Healthcare Information Services
Compare Stocks
2 / 10Stock Comparison
OMCL vs BDX
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Instruments & Supplies
OMCL vs BDX — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | ||
|---|---|---|
| Industry | Medical - Healthcare Information Services | Medical - Instruments & Supplies |
| Market Cap | $1.97B | $55.53B |
| Revenue (TTM) | $1.23B | $21.36B |
| Net Income (TTM) | $20M | $1.14B |
| Gross Margin | 43.5% | 46.5% |
| Operating Margin | 2.7% | 10.6% |
| Forward P/E | 22.4x | 12.3x |
| Total Debt | $204M | $19.18B |
| Cash & Equiv. | $197M | $851M |
OMCL vs BDX — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Omnicell, Inc. (OMCL) | 100 | 64.8 | -35.2% |
| Becton, Dickinson a… (BDX) | 100 | 103.0 | +3.0% |
Price return only. Dividends and distributions are not included.
Quick Verdict: OMCL vs BDX
Each card shows where this stock fits in a portfolio — not just who wins on paper.
OMCL is the clearest fit if your priority is sleep-well-at-night.
- Lower volatility, beta 1.34, Low D/E 16.6%, current ratio 1.43x
- +75.9% vs BDX's +51.8%
BDX carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 1 yrs, beta 0.66, yield 2.7%
- Rev growth 8.2%, EPS growth -0.5%, 3Y rev CAGR 5.0%
- 80.2% 10Y total return vs OMCL's 36.3%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 8.2% revenue growth vs OMCL's 6.5% | |
| Value | Lower P/E (12.3x vs 22.4x) | |
| Quality / Margins | 5.3% margin vs OMCL's 1.7% | |
| Stability / Safety | Beta 0.66 vs OMCL's 1.34 | |
| Dividends | 2.7% yield; 1-year raise streak; the other pay no meaningful dividend | |
| Momentum (1Y) | +75.9% vs BDX's +51.8% | |
| Efficiency (ROA) | 2.1% ROA vs OMCL's 1.0%, ROIC 4.3% vs 0.3% |
OMCL vs BDX — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
OMCL vs BDX — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
Income & Cash Flow (Last 12 Months)
BDX leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
BDX is the larger business by revenue, generating $21.4B annually — 17.4x OMCL's $1.2B. Profitability is closely matched — net margins range from 5.3% (BDX) to 1.7% (OMCL). On growth, OMCL holds the edge at +14.9% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ||
|---|---|---|
| RevenueTrailing 12 months | $1.2B | $21.4B |
| EBITDAEarnings before interest/tax | $111M | $4.2B |
| Net IncomeAfter-tax profit | $20M | $1.1B |
| Free Cash FlowCash after capex | $112M | $3.1B |
| Gross MarginGross profit ÷ Revenue | +43.5% | +46.5% |
| Operating MarginEBIT ÷ Revenue | +2.7% | +10.6% |
| Net MarginNet income ÷ Revenue | +1.7% | +5.3% |
| FCF MarginFCF ÷ Revenue | +9.1% | +14.7% |
| Rev. Growth (YoY)Latest quarter vs prior year | +14.9% | -10.6% |
| EPS Growth (YoY)Latest quarter vs prior year | +2.7% | -2.0% |
Valuation Metrics
BDX leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
At 26.3x trailing earnings, BDX trades at a 97% valuation discount to OMCL's 978.1x P/E. On an enterprise value basis, BDX's 14.7x EV/EBITDA is more attractive than OMCL's 23.6x.
| Metric | ||
|---|---|---|
| Market CapShares × price | $2.0B | $55.5B |
| Enterprise ValueMkt cap + debt − cash | $2.0B | $73.9B |
| Trailing P/EPrice ÷ TTM EPS | 978.10x | 26.29x |
| Forward P/EPrice ÷ next-FY EPS est. | 22.36x | 12.27x |
| PEG RatioP/E ÷ EPS growth rate | — | 1.59x |
| EV / EBITDAEnterprise value multiple | 23.56x | 14.65x |
| Price / SalesMarket cap ÷ Revenue | 1.66x | 2.54x |
| Price / BookPrice ÷ Book value/share | 1.63x | 1.73x |
| Price / FCFMarket cap ÷ FCF | 22.68x | 20.80x |
Profitability & Efficiency
Evenly matched — OMCL and BDX each lead in 4 of 8 comparable metrics.
Profitability & Efficiency
BDX delivers a 4.5% return on equity — every $100 of shareholder capital generates $5 in annual profit, vs $2 for OMCL. OMCL carries lower financial leverage with a 0.17x debt-to-equity ratio, signaling a more conservative balance sheet compared to BDX's 0.76x.
| Metric | ||
|---|---|---|
| ROE (TTM)Return on equity | +1.6% | +4.5% |
| ROA (TTM)Return on assets | +1.0% | +2.1% |
| ROICReturn on invested capital | +0.3% | +4.3% |
| ROCEReturn on capital employed | +0.3% | +5.4% |
| Piotroski ScoreFundamental quality 0–9 | 7 | 7 |
| Debt / EquityFinancial leverage | 0.17x | 0.76x |
| Net DebtTotal debt minus cash | $8M | $18.3B |
| Cash & Equiv.Liquid assets | $197M | $851M |
| Total DebtShort + long-term debt | $204M | $19.2B |
| Interest CoverageEBIT ÷ Interest expense | 18.41x | 4.09x |
Total Returns (Dividends Reinvested)
BDX leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in BDX five years ago would be worth $11,693 today (with dividends reinvested), compared to $3,062 for OMCL. Over the past 12 months, OMCL leads with a +75.9% total return vs BDX's +51.8%. The 3-year compound annual growth rate (CAGR) favors BDX at 1.6% vs OMCL's -12.6% — a key indicator of consistent wealth creation.
| Metric | ||
|---|---|---|
| YTD ReturnYear-to-date | -4.0% | +0.7% |
| 1-Year ReturnPast 12 months | +75.9% | +51.8% |
| 3-Year ReturnCumulative with dividends | -33.3% | +5.0% |
| 5-Year ReturnCumulative with dividends | -69.4% | +16.9% |
| 10-Year ReturnCumulative with dividends | +36.3% | +80.2% |
| CAGR (3Y)Annualised 3-year return | -12.6% | +1.6% |
Risk & Volatility
Evenly matched — OMCL and BDX each lead in 1 of 2 comparable metrics.
Risk & Volatility
BDX is the less volatile stock with a 0.66 beta — it tends to amplify market swings less than OMCL's 1.34 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. OMCL currently trades 78.8% from its 52-week high vs BDX's 74.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ||
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.34x | 0.66x |
| 52-Week HighHighest price in past year | $55.00 | $205.52 |
| 52-Week LowLowest price in past year | $24.23 | $100.31 |
| % of 52W HighCurrent price vs 52-week peak | +78.8% | +74.6% |
| RSI (14)Momentum oscillator 0–100 | 65.6 | 32.2 |
| Avg Volume (50D)Average daily shares traded | 559K | 2.5M |
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates OMCL as "Hold" and BDX as "Buy". Consensus price targets imply 32.0% upside for OMCL (target: $57) vs 12.8% for BDX (target: $173). BDX is the only dividend payer here at 2.72% yield — a key consideration for income-focused portfolios.
| Metric | ||
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Hold | Buy |
| Price TargetConsensus 12-month target | $57.20 | $172.85 |
| # AnalystsCovering analysts | 19 | 33 |
| Dividend YieldAnnual dividend ÷ price | — | +2.7% |
| Dividend StreakConsecutive years of raises | — | 1 |
| Dividend / ShareAnnual DPS | — | $4.17 |
| Buyback YieldShare repurchases ÷ mkt cap | +3.9% | +1.8% |
BDX leads in 3 of 6 categories — strongest in Income & Cash Flow and Valuation Metrics. 2 categories are tied.
OMCL vs BDX: Frequently Asked Questions
10 questions · data-driven answers · updated daily
01Is OMCL or BDX a better buy right now?
For growth investors, Becton, Dickinson and Company (BDX) is the stronger pick with 8.
2% revenue growth year-over-year, versus 6. 5% for Omnicell, Inc. (OMCL). Becton, Dickinson and Company (BDX) offers the better valuation at 26. 3x trailing P/E (12. 3x forward), making it the more compelling value choice. Analysts rate Becton, Dickinson and Company (BDX) a "Buy" — based on 33 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — OMCL or BDX?
On trailing P/E, Becton, Dickinson and Company (BDX) is the cheapest at 26.
3x versus Omnicell, Inc. at 978. 1x. On forward P/E, Becton, Dickinson and Company is actually cheaper at 12. 3x.
03Which is the better long-term investment — OMCL or BDX?
Over the past 5 years, Becton, Dickinson and Company (BDX) delivered a total return of +16.
9%, compared to -69. 4% for Omnicell, Inc. (OMCL). Over 10 years, the gap is even starker: BDX returned +80. 2% versus OMCL's +36. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — OMCL or BDX?
By beta (market sensitivity over 5 years), Becton, Dickinson and Company (BDX) is the lower-risk stock at 0.
66β versus Omnicell, Inc. 's 1. 34β — meaning OMCL is approximately 104% more volatile than BDX relative to the S&P 500. On balance sheet safety, Omnicell, Inc. (OMCL) carries a lower debt/equity ratio of 17% versus 76% for Becton, Dickinson and Company — giving it more financial flexibility in a downturn.
05Which is growing faster — OMCL or BDX?
By revenue growth (latest reported year), Becton, Dickinson and Company (BDX) is pulling ahead at 8.
2% versus 6. 5% for Omnicell, Inc. (OMCL). On earnings-per-share growth, the picture is similar: Becton, Dickinson and Company grew EPS -0. 5% year-over-year, compared to -83. 6% for Omnicell, Inc.. Over a 3-year CAGR, BDX leads at 5. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — OMCL or BDX?
Becton, Dickinson and Company (BDX) is the more profitable company, earning 7.
7% net margin versus 0. 2% for Omnicell, Inc. — meaning it keeps 7. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BDX leads at 11. 8% versus 0. 4% for OMCL. At the gross margin level — before operating expenses — BDX leads at 45. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is OMCL or BDX more undervalued right now?
On forward earnings alone, Becton, Dickinson and Company (BDX) trades at 12.
3x forward P/E versus 22. 4x for Omnicell, Inc. — 10. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for OMCL: 32. 0% to $57. 20.
08Which pays a better dividend — OMCL or BDX?
In this comparison, BDX (2.
7% yield) pays a dividend. OMCL does not pay a meaningful dividend and should not be held primarily for income.
09Is OMCL or BDX better for a retirement portfolio?
For long-horizon retirement investors, Becton, Dickinson and Company (BDX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
66), 2. 7% yield). Both have compounded well over 10 years (BDX: +80. 2%, OMCL: +36. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between OMCL and BDX?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
BDX pays a dividend while OMCL does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.